CHRISTIAN OTERO: Open Payments
NPI 1124648159 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,814 in 60 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $446 · 2025 $1,814
Food & beverage: $1,814
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 14 | $568 |
| ViiV Healthcare Company | 13 | $398 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $153 |
| Genentech USA, Inc. | 1 | $143 |
| Lilly USA, LLC | 2 | $143 |
| ABBVIE INC. | 5 | $104 |
| Merck Sharp & Dohme LLC | 4 | $95 |
| Theratechnologies Inc. | 3 | $79 |
| Novo Nordisk Inc | 2 | $40 |
| Abbott Laboratories | 2 | $38 |
Products named: CAPLYTA, APRETUDE, ZEPBOUND, Yeztugo, VRAYLAR, PIFELTRO, DOVATO, RUKOBIA.
Industry payments across FL — which companies pay providers there.
